News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week in Review: RuiYi (formerly Anaphore) Raises $15 Million For mAb Development


3/30/2014 3:04:48 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

March 29, 2014 --RuiYi, a San Diego-Shanghai biotech, raised $15 million in a Series B round to develop a portfolio of mAbs that bind to GPCR targets with high specificity; Golden Meditech of Hong Kong raised $101 million by selling its stake in a China mobile phone retailer, which it will put to use in China healthcare; Mapi Pharma, an Israeli API company with R&D operations in China, filed for a $46 million IPO on NASDAQ; MicroPort Medical received CFDA approval for its third-generation drug eluting stent; Lee’s Pharma of Hong Kong and its partners will start a global Phase III trial of an immunotherapy treatment for liver cancer; Jiangsu Nhwa Pharma will spend $64 million to build an API manufacturing facility in Xuzhou; and Jiangsu SR-BioPharma has broken ground on a new facility in Taizhou’s China Medical City, where it will make its HPV vaccine. More details….

Stock Symbols: (HK: 801; TW: 910801) (HK: 853) (HK: 0950)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES